Edition:
United States

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,486.25INR
6:21am EDT
Change (% chg)

Rs17.95 (+1.22%)
Prev Close
Rs1,468.30
Open
Rs1,468.70
Day's High
Rs1,489.50
Day's Low
Rs1,458.80
Volume
860,417
Avg. Vol
1,220,101
52-wk High
Rs2,129.00
52-wk Low
Rs1,280.00

LUPN.NS

Chart for LUPN.NS

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: 0.03
Market Cap(Mil.): Rs662,408.69
Shares Outstanding(Mil.): 451.14
Dividend: 7.50
Yield (%): 0.51

Financials

  LUPN.NS Industry Sector
P/E (TTM): 25.83 36.90 36.83
EPS (TTM): 56.85 -- --
ROI: -- 14.48 13.93
ROE: -- 15.27 14.84

BRIEF-Lupin gets FDA approval for generic Namenda XR capsules

* Receives FDA approval for Generic Namenda XR capsules Source text: http://bit.ly/2dgwkvs Further company coverage:

Sep 29 2016

German stocks - Factors to watch on September 27

FRANKFURT/BERLIN, Sept 27 The DAX top-30 index looked set to open 0.5 percent higher on Tuesday, according to premarket data from brokerage Lang & Schwarz at 0621 GMT. The following are some of the factors that may move German stocks:

Sep 27 2016

Indian shares fall more than 1 pct; Lupin down

Aug 10 Indian shares fell more than 1 percent on Wednesday, posting their worst fall in more than six weeks, as investors weighed whether a recent rally in equities may have been overdone, with drug maker Lupin Ltd down on concerns over its earnings outlook.

Aug 10 2016

Indian shares head for 2nd straight fall; Lupin drags

Aug 10 Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.

Aug 10 2016

UPDATE 2-Lupin's Q1 profit boosted by lower tax rate

* Shares close down 5.08 pct in Mumbai (Adds management comments from analyst call, bullets; updates share move)

Aug 09 2016

India's Lupin Q1 profit up 68 pct, beats estimates

MUMBAI, Aug 9 Lupin Ltd, India's third-largest drugmaker, reported a 68 percent rise in first-quarter profit, beating analysts' expectations.

Aug 09 2016

BRIEF-Silver Range acquires Itchen Property near Lupin Mine

* Silver Range acquires Itchen Property near Lupin Mine Source text for Eikon: Further company coverage:

Aug 04 2016

BRIEF-Silver range acquires Itchen Property near Lupin Mine

* Silver Range acquires Itchen Property near Lupin Mine Source text for Eikon: Further company coverage:

Aug 04 2016

India's Lupin to buy 21 branded drugs from Japan's Shionogi

MUMBAI, Aug 2 Indian drugmaker Lupin Ltd said it had agreed to buy a portfolio of 21 drugs from Japan's Shionogi & Co Ltd for 15.4 billion yen ($150 million), expanding its presence in its third-largest market.

Aug 01 2016

Lupin seeks to invalidate patent on Bausch & Lomb eye drug

Indian generic drugmaker Lupin Ltd is asking a court to invalidate a patent on Bausch & Lomb Inc's anti-inflammatory eye drug Prolensa as it seeks to make a generic version of the drug.

Jul 20 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : GlobalData
$300.00
Provider : Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.